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A b s t r a c t
Introduction: Kawasaki disease (KD) is an acute febrile illness of early child-
hood, characterised by vasculitis of the coronary and medium-sized arteries. 
The incidence of the disease differs worldwide, but the incidence of KD has 
not been established in Latvia. The aim of the study was to describe the ep-
idemiological characteristics and estimate the incidence rate and resistance 
to initial treatment of KD among hospitalised children in Latvia.
Material and methods: The  study was a  descriptive, population-based 
study, which used hospital discharge records of patients < 18 years old diag-
nosed with KD in the years 2012–2019. Incidence rate was calculated using 
the number of KD patients and corresponding national census data.
Results: There were 36 KD patients in Latvia. The median age at admission 
was 2.8 years, with 67% of cases under 5 years of age, and the male/female 
ratio was 1.3 : 1. The mean annual incidence rate was 1.3 per 100,000 chil-
dren 0–18 years old, and 2.9 per 100,000 for children < 5 years old. The mean 
length of hospital stay was 14 days. Coronary artery dilatation was recorded 
in 8% of the patients (all of whom were male). Every patient received intrave-
nous immunoglobulin (IVIG), with a median of 7 days from fever onset to IVIG 
administration. Refractory treatment was reported in 25% of cases.
Conclusions: This is the first epidemiological study of KD in Latvia. The in-
cidence rates are lower than those reported for other European countries. 
The percentage of refractory treatment was higher than in other studies.
Key words: Kawasaki disease incidence, refractory Kawasaki disease, IVIG 
treatment. 
Introduction
Kawasaki disease (KD) is one of  the  most common vasculitides of 
childhood [1]. It is typically a self-limited condition, with fever and mani-
festations of acute inflammation lasting for an average of 12 days without 
therapy [2]. However, complications such as coronary artery (CA) aneurysms 
may develop and lead to significant morbidity and mortality [3]. Kawasaki 
disease is the most prominent cause of acquired coronary artery disease 
(particularly coronary aneurysms and obstruction) in childhood [2]. Treat-
ment with intravenous immune globulin (IVIG) within the first 10 days 
of  illness reduces the prevalence of CA aneurysms fivefold when com-
pared with children not treated with IVIG [4, 5]. Early diagnosis is critical 
to achieve the  optimal treatment result. However, timely identification 
is challenging because the diagnosis is based upon nonspecific clinical 
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signs, and there is no definitive diagnostic test [3]. 
The diagnostics of KD have become more reco-
gnised only in recent years, and there are no offi-
cial data for Latvia about the incidence rate, patient 
characteristics, or received treatments. In this study, 
the authors analysed data taken from the database 
of hospital discharge codes regarding hospitalised 
children classified with a KD code for a period of 
8 years. This data were used to calculate the mean 
annual incidence of KD and the resistance to treat-
ment among children in Latvia, and to understand 
the correspondence with European data.
Risk stratification has proven useful in identify-
ing Japanese children treated for KD in Japan, who 
are at high risk of  IVIG resistance [6–8]. Further 
studies are needed to prospectively validate crite-
ria for identifying high-risk patients in other popu-
lations [6], therefore the Kobayashi risk score was 
calculated for each patient in this study. 
Material and methods
In Latvia, the Children’s Clinical University Hos-
pital (CCUH) is the  only children’s hospital in 
the country; therefore, patients with suspected KD 
from all Latvian regions are transferred to CCUH to 
receive their initial treatment. The data were col-
lected using the CCUH’s electronic database.
In this study, we identified all children who 
were discharged from the hospital with an Inter-
national Classification of  diseases (ICD) coding 
for KD (ICD10 M30.3). Retrospective medical data 
retrieved over 8 years (January 2012 to December 
2019) were collected and reviewed. The patients’ 
demographic, clinical, laboratory, echocardio-
graphic, and treatment data were recorded. All 
patients below 18 years of age diagnosed with KD 
were included in the study. Hospitalisation rates 
and estimates of annual incidence were expressed 
per 100,000 children, using national census esti-
mates for the years 2012–2019.
Resistance to the  treatment was defined as 
persistence of fever 36 hours after the end of ini-
tial IVIG infusion. Criteria that increases the  risk 
for IVIG resistance (Kobayashi risk score) was cal-
culated for each patient [6]:
•	 sodium	≤ 133 mmol/l (2 points),
•	 aspartate	aminotransferase	(AST)	≥ 100 int. units/l 
(2 points),
•	 C-reactive	protein	(CRP)	≥ 10 mg/dl (≥ 100 mg/l) 
(1 point), 
•	 neutrophils	≥ 80% of the white blood cell (WBC) 
count differential (2 points), 
•	 platelet	count	≤ 300,000/mm3 (1 point), 
•	 early	diagnosis,	with	initial	treatment	at	or	be-
fore the fourth day of illness (2 points), 
•	 age	≤ 12 months (1 point).
(Score ≥ 4 identifies patient with KD at a high 
risk of being resistant to IVIG).
Statistical analysis
The data were analysed using descriptive sta-
tistical methods.
Thirty-six patients were included in the  study 
during the  period 2012–2019. P  <  0.05 was con-
sidered statistically significant. All patient data 
were anonymised prior to use. The non-paramet-
ric Mann-Whitney U test was used to calculate 
the median treatment initiation day, for 2 indepen-
dent patient groups with and without CA dilatation. 
Ethical approval for this study was obtained 
from the Research Ethics Committee of Riga Stra-
dins University (RSU).
Results
During the study period of 2012–2019 there were 
36 patients with KD as the  primary diagnosis in 
Latvia. The median age at admission was 2.8 years 
(youngest 2 months, oldest 14 years). 67% of cas-
es occurred in patients under 5 years of  age, and 
the  male/female ratio was 1.3 : 1. The  mean an-
nual incidence rate was 1.3 per 100,000 children 
0–18 years old, and 2.9 per 100,000 for children 
below 5 years old (Table I). Incomplete KD was 
dia gnosed in 33% of cases. The average length of 
disease until hospitalisation was 6 days (mini-
mum 1 day, maximum 18 days). The mean number 
of days with disease before diagnosis was 10 (mini-
mum 4, maximum 21 days). The  median number 
of  days from fever onset to IVIG administration 
was 7. The mean length of hospital stay was 14 days, 
ranging from 6 to 32 days. Coronary dilatation was 
recorded in 3 (8%) patients, all of whom were male, 
and 67% of this group under the age of 12 months. 
The reported mortality rate was 0%, and 14% of pa-
tients were hospitalised in the  ICU. The epidemio-
logical and clinical features are shown in Table II. 
The laboratory test results are shown in Table III.
Table I. The  mean annual incidence of  Kawasaki 
disease in children under 5 years of age








2012 1 104,325 1.0
2013 3 101,271 3.0
2014 1 99,095 1.0
2015 4 100,386 4.0
2016 3 103,624 2.9
2017 7 106,973 6.5
2018 3 107,725 2.8
2019 2 106,168 1.9
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Coronary artery dilatation was present in 8% 
(3) of cases: in the first patient the coronary dila-
tation spontaneously regressed, and no dilatation 
was observed in the  follow-up diagnostic angio-
graphy; in the  second patient, coronary dilata-
tion persisted with LCA 3 mm, LMCA 4.1-4.4 mm 
(+2.1z) and RCA 4.9–5.0 mm (+2.7z). The patient 
is still being regularly observed by cardiologists. In 
the third patient the coronary dila tation was not 
present at the  time of  diagnosis but developed 
during follow-up. The dilatation currently persists 
without negative dynamics with LMCA 3.3 mm 
(+3.82z), RCA 3.5 mm (+4.9z).
All 36 patients received an IVIG infusion. Resis-
tance to treatment was observed in 25% of cases 
(19% received additional steroid pulse therapy 
and 6% received a second IVIG infusion).
Of the patients with increased risk for IVIG resis-
tance (19%), 29% received additional steroid pulse 
therapy. However, for 71% of  patients the  treat-
ment was successful with 1 infusion of IVIG. There 
were no statistically significant differences between 
higher risk and prolonged hospital stay.
In the  patient group that received additional 
steroid therapy treatment (19%), 71% had a low 
risk score of 1–2, and 29% had a risk score of 4. 
Those who received the second IVIG infusion had 
a low risk score of 1–2.
All patients with CA dilatation (8%) received 
1 IVIG infusion, had a risk score ≥ 3, and a treat-
ment initiation of ≥ 9 days.
Although the  number of  patients included is 
low, there were statistically significant differences 
between patients with and without CA dilatation, 
and day of treatment initiation. The treatment in 
all patients with CA dilatation was delayed, and 
the median day of treatment initiation was 19. For 
patients without CA dilatation, the  median day 
of treatment initiation was 7 (p < 0.05). 
Discussion
This is the  first epidemiologic study of  KD in 
Latvia. This study revealed a  mean annual inci-
dence of 2.9 per 100,000 children under 5 years 
of age, from 2012 to 2019. The mean incidence var-
ied between 1.0 and 6.5 during the 8-year study 
period. In comparison, the incidence rate in Europe 
for children under 5 years of age is 5–10 per 100,000 
[9], which suggests that the incidence rates in Lat-
via are lower than those reported for other Euro-
pean countries. This could be due to factors such 
as unawareness of  the  disease, the  resemblance 
of KD with other infectious diseases, and the lack 
of any specific diagnostic test. The incidence rate 
in recent years has not increased significantly. 
Sixty-seven per cent of  cases occurred in pa-
tients under 5 years of  age, which corresponds 
to the  northern European results. In comparison, 
Table II. Epidemiological and clinical features of pa-






< 5 years 24 (67)
5–18 years 12 (33)
Classical criteria
Conjunctival injection 32 (89)
Oral changes, lips 33 (92)
Changes in extremities 22 (61)
Polymorphous	exanthema 34 (94)








Central nervous system 
(positive meningeal symptoms)
5 (14)
Genitourinary (sterile pyuria) 6 (17)
Table III. Laboratory markers in children with Kawa-
saki disease
Variable Median  
(min.-max.)
CRP1 [mg/l] 79 (10–356)









Macrophage activation syndrome 0
1C-reactive protein. 2Erythrocyte sedimentation rate. 3Alanine amino-
transferase. 4N-terminal pro-B-type natriuretic peptide.
86.4% of Japanese KD patients were aged < 5 years, 
compared to only 67.8% in the northern European 
countries (Finland, Norway, Sweden), which re-
mains unexplained [10].
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Fever persisting for 5 or more days was the 
most frequent clinical manifestation of  KD, fol-
lowed by exanthema, changes of  lips, and the 
least frequent symptom – acute non-purulent 
lympha denitis [11].
Other studies describe the incidence of CA dila-
tation in 25–30% of patients with KD at the time 
of diagnosis in untreated cases [12–14]. The per-
centage of  CA dilatation in our study was 8%, 
which corresponds to the fivefold reduction of CA 
aneurysms in treated cases [4, 5].
The CA dilatation developed in patients with 
a  delayed treatment initiation. This once again 
proves that timely diagnostics and treatment are 
crucial in the management of KD. 
The percentage of  refractory treatment in our 
study was higher (25%) than in other studies with 
refractory KD, appearing in about 10–20% of pa-
tients who were initially treated with IVIG and as-
pirin [2, 15]. This could be due to the limited num-
ber of patients included in the study.
Additional steroids were given to 19% of chil-
dren in our study, who had a poor response to the 
initial dose of IVIG. 
Although the number of patients in the study 
was low, the known risk scores did not accurately 
reflect the resistance to treatment in this popula-
tion, which corresponds to the low sensitivity re-
ported in other studies for non-Japanese children 
[16–18]. It would be beneficial to validate a score 
for non-Japanese children, which could predict 
the risk of treatment failure.
However, this study does have some limitations. 
The  number of  KD-associated hospitalisations 
could have been underestimated, due to the  in-
clusion of misdiagnosed KD cases, or lack of inclu-
sion of cases in which patients were not hospital-
ised. Overall, the  number of  patients included in 
the  study is low; therefore, it is difficult to draw 
conclusions. The  retrospective character of  our 
study is also a  limitation, due to missing data in 
some parameters, such as clinical characteristics. 
As the  first Latvian study, this may serve as 
a useful tool for further clinical and epidemiologi-
cal studies.
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